These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37542714)

  • 1. Biosimilars for the next decade in Latin America: a window of opportunity.
    Bas TG
    Expert Opin Biol Ther; 2023; 23(8):659-669. PubMed ID: 37542714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
    de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
    J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
    Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
    J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
    Scheinberg M; Pineda C; Castañeda-Hernández G; Zarbá JJ; Damião A; Arantes LH; Jacobs I
    MAbs; 2018; 10(6):827-842. PubMed ID: 30156950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region.
    Alkhatib NS; Halloush S; Abraham I
    Expert Opin Biol Ther; 2023; 23(8):671-677. PubMed ID: 37493610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations in biosimilars: Latin America region.
    Rathore AS; Bhargava A
    Prep Biochem Biotechnol; 2021; 51(2):201-206. PubMed ID: 33529091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The landscape of biosimilars in Saudi Arabia: preparing for the next decade.
    Almutairi AR; Al-Samil AM; Alsayyari A; Yousef CC; Khan MA; Alhamdan HS; Al-Jedai A
    Expert Opin Biol Ther; 2023; 23(8):679-688. PubMed ID: 37503858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America.
    Ibarra-Cabrera R; Mena-Pérez SC; Bondani-Guasti A; García-Arrazola R
    Biotechnol Adv; 2013 Dec; 31(8):1333-43. PubMed ID: 23714280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars.
    Mosegui GBG; Antõnanzas F; de Mello Vianna CM; Rojas P
    Adv Rheumatol; 2021 Feb; 61(1):14. PubMed ID: 33632333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on Biosimilars in Asia.
    Tsai WC
    Curr Rheumatol Rep; 2017 Aug; 19(8):47. PubMed ID: 28718062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short and long-term economic implications of biosimilars.
    Al Meslamani AZ
    Expert Opin Biol Ther; 2024 Jul; 24(7):567-570. PubMed ID: 38231118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A health economic guide to market access of biosimilars.
    Simoens S; Vulto AG
    Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
    [No Abstract]   [Full Text] [Related]  

  • 15. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Regulatory and Commercial Environment for Biosimilars in Latin America.
    Azevedo VF; Sandorff E; Siemak B; Halbert RJ
    Value Health Reg Issues; 2012 Dec; 1(2):228-234. PubMed ID: 29702905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
    Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries.
    Klein K; Gencoglu M; Heisterberg J; Acha V; Stolk P
    BioDrugs; 2023 Mar; 37(2):235-245. PubMed ID: 36472773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.